Get started
Author

Sandrine Cure

Observed names: Cure, S, Cure, Sandrine, S Cure, S. Cure
ORCID: 0000-0002-8296-0771
Observed ORCID: 0000-0002-8296-0771
OpenAlex ID: A5019652605
Disease burden and economic impact of diagnosed non‐alcoholic steatohepatitis in five European countries in 2018: A cost‐of‐illness analysis
2021 · Jörn M. Schattenberg, Jeffrey V. Lazarus, et al. · Liver International · 147
Chronic insomnia, quality-of-life, and utility scores: Comparison with good sleepers in a cross-sectional international survey
2011 · Damien Léger, Charles M. Morin, et al. · Sleep Medicine · 142
Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study
2013 · G. Hechmati, S. Cure, et al. · Journal of Medical Economics · 63
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018
2021 · Alice Morgan, Sally L. Sansom, et al. · The European Journal of Health Economics · 49
PDF
Systematic Literature Review and Meta-Analysis of Diagnostic Test Accuracy in Alzheimer's Disease and Other Dementia Using Autopsy as Standard of Truth
2014 · Sandrine Cure, Keith Abrams, et al. · Journal of Alzheimer s Disease · 49
Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C
2015 · Alena M. Pfeil, Oliver Reich, et al. · PLoS ONE · 48
Preferences of Patients with Diabetes Mellitus for Inhaled versus Injectable Insulin Regimens
2008 · Jeremy Chancellor, Samuel Aballéa, et al. · PharmacoEconomics · 39
Patients' preferences and health utility assessment with SF‐6D and EQ‐5D in patients with chronic hepatitis C treated with sofosbuvir regimens
2014 · M. Stepanova, F. Nader, et al. · Alimentary Pharmacology & Therapeutics · 38
Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients
2013 · Sandrine Cure, Florence Bianic, et al. · Journal of Medical Economics · 31
PDF
Cost–utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan
2016 · Ataru Igarashi, Wentao Tang, et al. · Current Medical Research and Opinion · 29
Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients
2013 · Sandrine Cure, Florence Bianic, et al. · Journal of Medical Economics · 27
PDF
Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy
2015 · Sandrine Cure, Ines Guerra, et al. · Journal of Medical Economics · 26
PDF
Cost-Effectiveness of Highly Purified Omega-3 Polyunsaturated Fatty Acid Ethyl Esters in the Treatment of Chronic Heart Failure: Results of Markov Modelling in a UK Setting
2011 · Martin R. Cowie, Sandrine Cure, et al. · European Journal of Heart Failure · 26
PDF
Cost‐effectiveness of sofosbuvir for the treatment of chronic hepatitis C ‐infected patients
2015 · S. Cure, I. Guerra, et al. · Journal of Viral Hepatitis · 25
PDF
Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland
2016 · Erkki Soini, Taru Hallinen, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 21
Efficacy of treatment options for complicated urinary tract infections including acute pyelonephritis: a systematic literature review and network meta-analysis
2025 · Florian Wagenlehner, Verónica Rico Caballero, et al. · Journal of Comparative Effectiveness Research · 19
Cost–utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan
2016 · Ataru Igarashi, Wentao Tang, et al. · Current Medical Research and Opinion · 18
Efficacy of telaprevir and boceprevir in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis
2012 · S. Cure, J. Diels, et al. · Current Medical Research and Opinion · 18
Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom
2017 · A.H. Young, L. Evitt, et al. · Journal of Affective Disorders · 15
Cost Utility of Telaprevir–PR (Peginterferon–Ribavirin) Versus Boceprevir–PR and Versus PR Alone in Chronic Hepatitis C in The Netherlands
2014 · Aikaterini Vellopoulou, Michel van Agthoven, et al. · Applied Health Economics and Health Policy · 13
EASL-AASLD Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis
2026 · Cynthia Levy, Ana Lleo, et al. · Journal of Hepatology · 11
Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens
2015 · Sandrine Cure, Florence Bianic, et al. · PLoS ONE · 11
PDF
A retrospective database study comparing treatment outcomes and cost associated with choice of fixed-dose inhaled corticosteroid/long-acting β2-agonists for asthma maintenance treatment in Germany
2008 · S. Aballéa, S. Cure, et al. · International Journal of Clinical Practice · 11
PDF
Cost-Utility Analysis Of Sofosbuvir For Treatment Of Genotype2 Chronic Hepatitis C In Japan
2014 · A. Igarashi, W. Tang, et al. · Value in Health · 6
PDF
PCN115 Cost of Skeletal-Related Events (SREs) in Patients with Bone Metastases to solid Tumours Based on the Health Resource Utilisation (HRU) Collected in a Prospective European Multinational Observational Study
2011 · G. Hechmati, S. Cure, et al. · Value in Health · 6
Works count: 73
Citation count: 926
H-index: 18
I10-index: 23
Year
Topic
Type